Mast cell leukemia with novel BRAF variant and concomitant atypical KIT variant

Ricardo Sánchez, María Liz Paciello, Rosa M Ayala, Leyre Lorza, Teresa Cedena, M Pilar Martínez and Joaquín Martínez-López. Molecular Landscape and Clonal Evolution of Acute Mast Cell Leukemia: Case Study. 2022. Efrati, 1957, Mast cell leukemia? Malignant mastocytosis with leukemia-like manifestations, Blood, 12, 869, 10.1182/blood.V12.10.869.869 Gotlib, 2013, International working group-myeloproliferative neoplasms research and treatment (IWG-MRT) & european competence network on mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis, Blood, 121, 2393, 10.1182/blood-2012-09-458521 Valent, 2017, Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts, Blood, 129, 1420, 10.1182/blood-2016-09-731893 Baghestanian, 1996, A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone, Leukemia, 10, 159 Georgin-Lavialle, 2013, Mast cell leukemia, Blood, 121, 1285, 10.1182/blood-2012-07-442400 Gotlib, 2016, Efficacy and safety of midostaurin in advanced systemic mastocytosis, N Engl J Med, 374, 2530, 10.1056/NEJMoa1513098 Valent, 2015, Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage, Ann Hematol, 94, 223, 10.1007/s00277-014-2207-9 Youk, 2016, A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data, Blood Res, 51, 17, 10.5045/br.2016.51.1.17 Bodemer, 2010, Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations, J Invest Dermatol, 130, 804, 10.1038/jid.2009.281 Kanakura, 1994, Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line, Leukemia, 8, S18 Blechman, 1993, Structure-function analyses of the kit receptor for the steel factor, Stem Cells, 11, 12, 10.1002/stem.5530110804 Hägglund, 2014, Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis, Med Oncol, 31, 123, 10.1007/s12032-014-0123-4 Yoon, 2006, The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions, Growth Factors, 24, 21, 10.1080/02699050500284218 Cohn, 2017, BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study, Onco Targets Ther, 10, 965, 10.2147/OTT.S120440 Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/S0092-8674(04)00215-6 Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 Yao, 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS, Nature, 548, 234, 10.1038/nature23291 Zheng, 2015, Clinical detection and categorization of uncommon and concomitant mutations involving BRAF, BMC Cancer, 24, 779, 10.1186/s12885-015-1811-y Miranda, 2012, KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors, Clin Cancer Res, 18, 1769, 10.1158/1078-0432.CCR-11-2230